Research team pinpoints immune changes in blood of melanoma patients on PD-1 drugs that put potential biomarker within reach

A simple blood test can detect early markers of "reinvigorated" T cells and track immune responses in metastatic melanoma patients after initial treatment with the anti-PD-1 drug pembrolizumab, scientists report.